Latest Insider Transactions at Logic Bio Therapeutics, Inc. (LOGC)
This section provides a real-time view of insider transactions for Logic Bio Therapeutics, Inc. (LOGC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LogicBio Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LogicBio Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 16
2022
|
Daniel Gruskin Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,331
-100.0%
|
-
|
|
Nov 16
2022
|
Leon Chen Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,333
-100.0%
|
-
|
|
Nov 16
2022
|
Richard A Moscicki Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,916
-100.0%
|
-
|
|
Nov 16
2022
|
Frederic Chereau President, CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
253,811
-100.0%
|
-
|
|
Nov 16
2022
|
Michael S Wyzga Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,141
-100.0%
|
-
|
|
Nov 16
2022
|
Mark J Enyedy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,921
-100.0%
|
-
|
|
Nov 16
2022
|
Mark A Kay Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
784,557
-100.0%
|
-
|
|
Jan 12
2022
|
Cecilia Jones Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,175
-36.62%
|
$4,350
$2.01 P/Share
|
|
Jan 11
2022
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,939
+50.0%
|
-
|
|
Aug 09
2021
|
Daniel Gruskin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,467
-30.58%
|
$5,868
$4.35 P/Share
|
|
Aug 06
2021
|
Daniel Gruskin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,798
+50.0%
|
-
|
|
Apr 16
2021
|
Frederic Chereau President, CEO |
SELL
Open market or private sale
|
Direct |
7,542
-2.89%
|
$37,710
$5.73 P/Share
|
|
Apr 16
2021
|
Kyle Chiang Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,977
-11.29%
|
$14,885
$5.73 P/Share
|
|
Apr 15
2021
|
Frederic Chereau President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
23,414
+8.22%
|
-
|
|
Apr 15
2021
|
Kyle Chiang Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,360
+26.2%
|
-
|
|
Jan 01
2021
|
Richard A Moscicki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,916
+50.0%
|
-
|
|
Jan 01
2021
|
Michael S Wyzga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,141
+50.0%
|
-
|
|
Jan 01
2021
|
Mark J Enyedy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,921
+50.0%
|
-
|
|
Jan 01
2021
|
Leon Chen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,298
+50.0%
|
-
|
|
Jan 01
2021
|
Mark A Kay Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,199
+50.0%
|
-
|
|
Dec 10
2020
|
Daniel P O'Connell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,513
+50.0%
|
-
|
|
Oct 01
2020
|
Erez Chimovits Director |
BUY
Open market or private purchase
|
Indirect |
1,481,482
+25.61%
|
$8,888,892
$6.0 P/Share
|
|
Oct 01
2020
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,481,482
+25.61%
|
$8,888,892
$6.0 P/Share
|
|
Sep 28
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
273,584
-10.3%
|
$1,915,088
$7.54 P/Share
|
|
Sep 25
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
174,219
-6.16%
|
$1,219,533
$7.08 P/Share
|
|
Sep 24
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
38,514
-1.34%
|
$269,598
$7.63 P/Share
|
|
Aug 13
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
159
-0.01%
|
$1,272
$8.75 P/Share
|
|
Aug 12
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,335
-0.05%
|
$10,680
$8.79 P/Share
|
|
Jul 29
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,709
-0.09%
|
$21,672
$8.78 P/Share
|
|
Jul 22
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,651
-0.78%
|
$203,859
$9.0 P/Share
|
|
Jul 20
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
36,983
-1.26%
|
$332,847
$9.25 P/Share
|
|
Jul 17
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
31,101
-1.05%
|
$279,909
$9.24 P/Share
|
|
Jul 16
2020
|
Arix Bioscience PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
16,332
-0.55%
|
$130,656
$8.56 P/Share
|
|
Oct 23
2018
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,190,000
+8.8%
|
$11,900,000
$10.0 P/Share
|
|
Oct 23
2018
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
5,276,783
+40.08%
|
-
|